BIOMAT Database Logo BIOMAT Database Logo

Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. 2003

Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Department of Pediatric Hematology, Children's Hospital III, Frankfurt, Germany.

Ina 24-month-old girl with acute lymphoblastic leukemia and invasive aspergillosis, only combination therapy with liposomal amphotericin B and caspofungin achieved a good response. Combination therapy could be a useful treatment option in children with invasive fungal disease, but before it can be routinely recommended, carefully controlled in vivo studies and well-designed randomized clinical trials are needed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Invasive esophageal aspergillosis associated with acute myelogenous leukemia: successful therapy with combination caspofungin and liposomal amphotericin B.
January 2007, Pediatric hematology and oncology,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
December 2007, Cancer,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Caspofungin versus liposomal amphotericin B for empirical therapy.
January 2005, The New England journal of medicine,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Possible hepatosplenic candidiasis treated with liposomal amphotericin B and caspofungin combination.
May 2006, The Journal of infection,
Ziju Elanjikal, and Jan Sörensen, and Helga Schmidt, and Wolfgang Dupuis, and Kathrin Tintelnot, and Günter Jautzke, and Thomas Klingebiel, and Thomas Lehrnbecher
Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
October 2003, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!